Study design
artery atherosclerosis, Stroke
STROKE
HOPES2 (Head-dOwn Position for acutE moderate ischemic Stroke with large artery atherosclerosis) was an investigator-initiated, prospective, randomized, open-label, blinded-endpoint (PROBE), multicenter and phase-2 trial to assess the feasibility, safety and possible efficacy of two weeks of HDP in moderate AIS-LAA patients within 24 h from symptom onset. Due to the small sample size and no involving genetic information and materials, this trial was waived approval from China’s Ministry of Science and Technology related to the export of genetic information and materials. The trial was conducted at 10 medical sites (Supplementary Note 